Stryker Corporation : Stryker Announces $250 Million Accelerated Share Repurchase Program

    Stryker Corporation : Stryker Announces $250 Million Accelerated Share
                              Repurchase Program

Kalamazoo, Michigan - March 1, 2013 - Stryker Corporation (NYSE:SYK) announced
today it has entered into an Accelerated Share Repurchase agreement (ASR) with
JPMorgan Chase Bank, NA to repurchase an aggregate of $250 million of the
Company's common stock. The ASR is part of the Company's existing share
repurchase authorization that was increased by the Board of Directors to $1.0
billion in December 2012. 

"We continue to be committed to a capital allocation strategy that includes
acquisitions, dividends and share repurchases," said Kevin A. Lobo, President
and Chief Executive Officer of Stryker. "This accelerated share repurchase is
consistent with this strategy, which prioritizes acquisitions for sales growth
while simultaneously returning capital to shareholders."

Under the ASR agreement, Stryker will receive approximately 3.6 million shares
at the inception of the ASR. The total number of shares ultimately
repurchased under the agreement will be determined upon the final settlement,
using prices based generally on the average of the daily volume-weighted
average price of the Company's common stock over a period of time expected to
end in the first half of 2013. The ASR will be funded through existing cash
on hand. The ASR will reduce the Company's existing share repurchase
authorization to approximately $750 million at the final settlement of the

Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies, including reconstructive, medical and
surgical, and neurotechnology and spine products to help people lead more
active and more satisfying lives. For more information about Stryker, please


For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or

This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening of
economic conditions that could adversely affect the level of demand for our
products; pricing pressures generally, including cost-containment measures
that could adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions; unanticipated
issues arising in connection with clinical studies and otherwise that affect
U.S. Food and Drug Administration approval of new products; changes in
reimbursement levels from third-party payors; a significant increase in
product liability claims; the ultimate total cost with respect to the
Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system and the 2.3
percent medical device excise tax; changes in financial markets; changes in
the competitive environment; our ability to integrate acquisitions, including
the acquisition of Trauson Holdings Company Limited; and our ability to
realize anticipated cost savings as a result of workforce reductions and other
restructuring activities. Additional information concerning these and other
factors are contained in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.